Objectives: Quality indicators (QIs) are evidence-based processes of care designed to represent the current standard of care. Reproductive health QIs for the care of patients with systemic lupus erythematosus (SLE) have recently been developed, and examine areas such as pregnancy screening for autoantibodies, treatment of pregnancy-associated antiphospholipid syndrome, and contraceptive counseling. This study was designed to investigate our performance on these QIs and to explore potential gaps in care and demographic predictors of adherence to the QIs in a safety-net hospital. Methods: We performed a record review of patients with a diagnosis of SLE at Denver Health Medical Center (DH) through an electronic query of existing medical records and via chart review. Data were limited to female patients between the ages of 18 and 50 who were seen between July 2006 and August 2011. Results: A total of 137 female patients between the ages of 18 and 50 were identified by ICD-9 code and confirmed by chart review to have SLE. Of these, 122 patients met the updated 1997 American College of Rheumatology SLE criteria and had intact reproductive systems. Only 15 pregnancies were documented during this five-year period, and adherence to autoantibody screening was 100 percent. We did not have any patients who were pregnant and met criteria for pregnancy-associated antiphospholipid syndrome. Sixty-five patients (53%) received potentially teratogenic medications, and 30 (46%) had documented discussions about these medications' potential risk upon their initiation. Predictors of whether patients received appropriate counseling included younger age (OR 0.92, CI 0.87-0.98) and those who did not describe English as their primary language (OR 0.24, CI 0.07-0.87) in the multivariate analysis. Conclusions: We were able to detect an important gap in care regarding teratogenic medication education to SLE patients of childbearing potential in our public health academic clinic, as only one in two eligible patients had documented appropriate counseling at the initiation of a teratogenic medication. Lupus (2015) 24, 203-209.
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Background
Quality indicators (QIs) are rigorously constructed, evidence-and experience-based measures thought to represent the current standard of care. In an effort to analyze and improve the quality of health care delivery, QIs have been developed in many areas of rheumatologic practice such as gout, osteoarthritis, and rheumatoid arthritis. 1 Recently, QIs have been developed for systemic lupus erythematosus (SLE) and address such areas as drug monitoring, laboratory screening, and reproductive health. 2 Even though SLE has a lower prevalence than other chronic rheumatologic conditions (i.e. rheumatoid arthritis) in the general population, its morbidity burden is significant. 3 Diagnosis of SLE is frequently made in young adults, predominantly women, during the reproductive years. 3 Because of the onset and frequency of SLE in women of reproductive age, it is paramount to analyze the issues surrounding reproductive health in clinical practice. As part of a larger project, three reproductive health QIs for SLE have been developed (see Figure 1 ). 4 These three QIs recommend exploring areas that need to be monitored to best promote successful reproductive outcomes. These QIs recommend testing for specific antibodies in women who are anticipating pregnancy (QI1), treatment of pregnancy-associated antiphospholipid antibody syndrome (pregnancy-APS) with heparin and aspirin (QI2), and counseling of women with reproductive potential who are prescribed a teratogenic medication (QI3). To date, no evaluation of these QIs' application to a real-life setting has been conducted.
In this study, we systematically applied the SLE reproductive health QIs to a safety-net health system, using a combined approach for data capture from electronic health records as well as chart review. Our primary goal was to examine adherence to SLE QIs, feasibility of performing these measures, and sociodemographic predictors of higher adherence to the QIs.
Methods
Study population
Denver Health (DH), and its associated 20 community clinics, is an urban academic safety-net hospital system with 400,000 annual outpatient visits and 26,000 annual inpatient visits. We first identified individuals with SLE who were seen in the DH system between July 2006 and August 2011 via International Classification of Diseases, Ninth revision, Clinical Modification (ICD-9-CM) code 710.0 as identified from the integrated electronic health record. This population was then limited to female patients between the ages of 18 and 50, and chart reviews were performed (by AN and RF) to confirm that individuals met the American College of Rheumatology (ACR) criteria for SLE 9 and to evaluate if the patient was able to conceive (pre-menopausal, without tubal ligation or hysterectomy). A total of 156 chart abstractions were performed, several individuals were excluded for failing to meet SLE classification criteria, and one was excluded because of incarceration.
Variables
Outcome variables QI1 (evaluation of pregnancy-linked SLE screenings) outcome variables included antiphospholipid antibody testing (anticardiolipin antibody immunoglobulin G and IgM, B2 glycoprotein antibody IgG and IgM, dilute Russell's viper venom time, and lupus anticoagulant confirmatory testing), and SSA and SSB antibodies. Charts of the 15 pregnant patients were reviewed for completion of this QI. For QI2 (evaluation of appropriate pregnancy-APS treatment), we performed a manual chart review to identify pregnant patients who met criteria for pregnancy-APS and to evaluate for appropriate treatment algorithms (heparin and aspirin). Finally, for QI3 (counseling women of childbearing ability regarding the teratogenic potential of medications), we performed a manual chart review and recorded whether providers documented counseling of the teratogenic potential in the rheumatology visit that the medication was initiated. Rheumatologic medications that we considered to require counseling regarding risk included: methotrexate, azathioprine, leflunomide, mycophenolate mofetil, cyclosporine, cyclophosphamide, and thalidomide. We did not include hydroxychloroquine as this medication is thought to be relatively safe in pregnancy. 6 As a measure of feasibility, we recorded the time spent extracting each of the QIs.
Sociodemographic and disease variables
Sociodemographic data were collected from the Denver Health Data Warehouse, a repository of data compiled from DH's electronic health record. The query included age, gender, race/ethnicity, primary language, use of interpreter services, primary source of payment, income level (below the federal poverty level, yes/no), C3 and C4 complement levels, anti-double-stranded DNA (dsDNA), and history of pregnancy discharge diagnoses after the index encounter during the study period. We included C3 and C4 complement levels (mg/dl) and dsDNA (IU/ml) as surrogates for disease activity.
Statistical analyses
We calculated performance on each SLE QI measure, defined as the proportion of eligible patients receiving the recommended care. For QI3, chisquare testing was used to seek unadjusted differences in the proportion of patients prescribed teratogenic medications who received teratogenic risk and/or contraceptive counseling, and patient Application and feasibility of SLE reproductive health care quality indicators I Quinzanos et al.
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Lupus Description QI1 Two-part screening task for pregnant women or women contemplating pregnancy:
1)
Testing for SSA and SSB antibodies prior to pregnancy, and documenting in the chart within the first trimester.
Reasoning: Obstetric guidelines a identify seropositive patients to have increased risk of giving birth to children with congenital heart block and/or neonatal lupus syndrome. 5, 6 Evidence: There is no documented evidence that these tests improve outcomes, but experts have underlined their importance in determining appropriate steps to monitor the pregnancy.
2) Documentation of antiphospholipid antibodies (aPL) within four weeks of pregnancy, to reflect tests conducted in the six months prior.
Reasoning and evidence: Several guidelines b describe pregnancies with aPL as being linked to poorer outcomes, although it is difficult to discern whether these are due to systemic lupus erythematosus (SLE) or aPL positivity.
QI2
Focuses on the appropriate treatment of pregnancy associated primary antiphospholipid antibody syndrome (pregnancy-APS).
Reasoning: For patients with a history of confirmed pregnancy-APS, the risk of poor obstetric results is significant.
Evidence: A recent Cochrane review found that unfractionated heparin plus aspirin (ASA) was superior to ASA alone (relative risk (RR) 0.46, 95% confidence interval (95% CI) 0.29-0.71). 7 And current obstetric guidelines suggest that prophylaxis with either low molecular weight heparin or unfractionated heparin and low-dose ASA, increased the live birth rate. c QI3 Highlights the need for counseling regarding risk and contraception in women taking potentially teratogenic disease-modifying antirheumatic drugs. Documentation of counseling should be in the medical chart.
Reasoning and evidence: Data regarding counseling of SLE patients on the teratogenic potential of medications are lacking.
However, in the general population fewer than 20% of women receiving teratogenic drugs are given appropriate counseling and approximately 6% of pregnancies in the United States are exposed to potentially teratogenic class D or X medications, 8 Fifteen pregnancies were documented during this five-year period. Performance on the QI1 regarding antibody testing was 100%. We were unable to assess QI2, as no pregnant patients in our chart review met criteria for pregnancy-APS. For QI3 approximately one-half of the patients (65/122 patients, 53%) received potentially teratogenic medications, and of these, 46% had documented counseling (30/65 patients).
Of the 65 patients who received potentially teratogenic medications, only 30 patients (46%) had documented discussions at the time of the medication's initiation about the potential teratogenic risks. The only significant difference between those with and without documented counseling for teratogenic medications was age (average age 29 vs. 35 years, respectively, p value 0.0073) ( Table 2 ).
In our unadjusted logistic regression (Table 3) , the only statistically significant variables that predicted the documentation of appropriate counseling were younger age and non-English as the patient's primary language. Both of these variables were inversely related to documentation of appropriate counseling. That is, increasing age had a lower odds ratio (OR) of receiving counseling (OR 0.93, 95% confidence interval (CI) 0.87-0.98) and English-speakers had a lower OR of documented appropriate counseling (OR 0.29, 95% CI 0.09-0.96). These relationships remained statistically significant in the multivariate analysis that controlled for the effect of other demographic characteristics (p value 0.009, 95% CI 0.86-0.98 for age and p value 0.030, 95% CI 0.07-0.87 for English). None of the disease activity variables were statistically significantly different between counseled and non-counseled patients. 
Discussion
In our study, we systematically applied the reproductive SLE health QIs to an academic safety-net health system using electronic data capture as well as chart review, and we were able to quantify the time burden required to extract this information using currently available data streams. As a result, we detected an important gap in care in our system regarding the documented education of childbearing lupus patients about the potential teratogenic risk of immunosuppressive medications.
Only half of the patients in our study received counseling. This has been documented in previous studies. In 2007 Schwartz et al. found that many women of childbearing potential who filled class D or X medications had no contraceptive method dispensed, had not been sterilized, and had no documentation of contraceptive counseling in the two years prior. 8 Similarly, Andrade et al. studied eight health-managed organization populations and found that 6% of pregnant women had received United States Food and Drug Administration (US FDA) category D or X drugs during the 270 days before delivery. 10 Other studies of European populations using the US FDA and other medication risk classifications systems suggest an even higher use of potentially harmful drugs during pregnancy-approximately 20% to 60%. 11, 12 Potential barriers to adherence to these QIs include poor documentation, lack of time, or perhaps a focus on lupus activity that can be organ threatening. Implementation of a checklist in the electronic medical record when a new medication with teratogenic potential is prescribed to a woman of childbearing age could be a potential solution. In fact, clinical decision support has been proposed recently as a way to alert clinicians to the need for teratogenic risk counseling. It has had modest but encouraging results, and further modification and evaluation of such support systems remain needed. 13 Involving pharmacists in efforts to alert women about medication risks may also be beneficial.
Interestingly, non-English as the patient's primary language predicted the documentation of counseling with the use of a new teratogenic medication. Perhaps providers may have assumed that primary English speakers possess greater familiarity with the teratogenic effects of DMARDs, or that the presence of an interpreter added either formality or additional time to the visit that encouraged counseling and/or documentation of counseling. Further studies are needed to unravel the underlying reasons for this association.
Younger patients were also more likely to receive counseling, which is not surprising, and has been documented in other studies. 8 However, this identifies a gap in quality, as older patients of childbearing potential need to take precautions to prevent conception after teratogenic exposures as well.
QI measures have been shown to help health care providers to identify gaps in care 14 and to study possible barriers to their completion. In some cases there is a need to modify the QI because its lack of utility or validity, but in other scenarios we need to optimize its measurements.
Electronic specification of these measures may reduce the collection burden. Compilation of data using structured fields in the electronic health record will increase the likelihood of these data being useful. Manual chart review may not be feasible for practices with limited resources or for rapid-cycle quality improvement. Instead, future studies should focus on minimally burdensome electronic data capture with real-time clinical decision support and performance feedback. There has been some success in this area with the use of disease registries. Examples of this include the American College of Cardiology and the American Thoracic Society that have conducted research and implemented impressive quality improvement programs throughout their registries. The ACR has also created the Rheumatology Clinical Registry to facilitate quality reporting for practicing rheumatologists in areas like rheumatoid arthritis QI measures. These can certainly serve as a useful model for the field moving forward in SLE. 15 Limitations of this study include its retrospective nature. Additionally, for QI1 and QI2, we documented only 15 pregnancies during the five-year time period and thus it is difficult to generalize regarding adherence to QI1 and/or QI2. Extraction of the QIs from the medical record was technically feasible but tedious. Additionally, we did not include clinical features as a marker for disease activity as our clinic still uses a paper charting system, and this would be beyond the scope of our ability at this time. For QI3, the lack of documentation does not necessarily indicate that counseling did not occur. We also must take with caution the significance of a patient being a non-English speaker, given the wide confidence intervals. Counseling could also be affected by some unmeasured factors, examples of which include religious practices affecting contraception and the patient's desire for pregnancy, which may or not be expressed at a visit.
Strengths of this study include its comparatively large sample size, access to a disadvantaged sociodemographic population, and medical chart review, which remains the gold standard for evaluating performance on QIs.
In summary, our study applied recently developed reproductive QIs to a large, culturally diverse, medical center to determine adherence and the feasibility of QI application. We found that more than one in two patients did not receive documented contraceptive counseling when placed on teratogenic medications, and that older and English-speaking SLE patients were less likely to receive contraceptive counseling. While the lack of documentation does not preclude the counseling having occurred, the systematic application of QIs in our system has minimally identified a gap in quality of documentation. Future studies should focus on interventions that improve quality in this area while minimizing data collection burden for the practice. 
